La Montagne

BITT Announces FDA Acceptance of IND for TNFR2 Antibody

Retrieved on: 
Friday, August 18, 2023

Boston Immune Technologies and Therapeutics, Inc. (BITT), a clinical stage biotechnology company developing novel tumor necrosis factor superfamily receptor (TNFSR) antagonist antibodies, announced today that the Food and Drug Administration (FDA) has cleared BITT’s Investigational New Drug application (IND) for a Phase I trial of BITT2101 (anti-TNFR2) in patients with relapsed or refractory Non-Hodgkin’s lymphomas.

Key Points: 
  • Boston Immune Technologies and Therapeutics, Inc. (BITT), a clinical stage biotechnology company developing novel tumor necrosis factor superfamily receptor (TNFSR) antagonist antibodies, announced today that the Food and Drug Administration (FDA) has cleared BITT’s Investigational New Drug application (IND) for a Phase I trial of BITT2101 (anti-TNFR2) in patients with relapsed or refractory Non-Hodgkin’s lymphomas.
  • “We are excited to have approval to bring our lead antibody into clinical trials,” said Russell LaMontagne, Co-Founder and Chief Executive Officer of BITT.
  • “This is the first antibody from BITT’s TNF Superfamily platform to enter the clinic and the first opportunity to demonstrate the novelty and utility of our proprietary dominant antagonist antibodies.”
    “The elevated levels of soluble TNFR2 (sTNFR2) in these lymphoma subtypes suggest that TNFR2 may play a significant role in progression and response to first line therapy.
  • As the escalation arm progresses, we are actively exploring validation of sTNFR2 in multiple cancers including solid tumors for potential expansion arms,” added LaMontagne.

Trivver Develops Groundbreaking Authenticity Scanner to Help Minimize NFT Fraud

Retrieved on: 
Tuesday, August 16, 2022

NEWPORT BEACH, Calif., Aug. 16, 2022 /PRNewswire/ -- Trivver is pleased to announce its Non-Fungible Token (NFT) authenticity scanner has been successfully awarded the fast growing company's latest U.S. patent. 

Key Points: 
  • Trivver today received its latest patent for its cutting edge NFT authenticity scanner that is designed to instantly verify ownership of digital assets.
  • NEWPORT BEACH, Calif., Aug. 16, 2022 /PRNewswire/ -- Trivver is pleased to announce its Non-Fungible Token (NFT) authenticity scanner has been successfully awarded the fast growing company's latest U.S. patent.
  • Although the recent surge in NFT marketplace sales and activity has subsided, substantial activity remains in the space.
  • "Open the app, scan the NFT from a smart device and Trivver instantly reports whether or not the NFT is fraudulent or authentic.

IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development

Retrieved on: 
Tuesday, July 12, 2022

Kenneth R. LaMontagne, Ph.D., joins the company as Senior Vice President, Business Development, to advance the companys partnership strategy and execute collaborative transactions to promote growth.

Key Points: 
  • Kenneth R. LaMontagne, Ph.D., joins the company as Senior Vice President, Business Development, to advance the companys partnership strategy and execute collaborative transactions to promote growth.
  • We are delighted to welcome Ken, who brings great experience and relationships across biotech, pharma and in cellular therapies, to lead IN8bios global business development activities.
  • Prior to joining IN8bio, Dr. LaMontagne was a Vice President in Business Development at Artisan Bio, a cell engineering company developing next-generation cellular therapies.
  • IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors.

Zerigo Health Expands Board of Directors

Retrieved on: 
Tuesday, December 14, 2021

Zerigo Health , which delivers the only connected light therapy solution for treating chronic skin conditions at home or on the go, today announced the appointments of Joseph E. Giles and Christina LaMontagne to the companys Board of Directors.

Key Points: 
  • Zerigo Health , which delivers the only connected light therapy solution for treating chronic skin conditions at home or on the go, today announced the appointments of Joseph E. Giles and Christina LaMontagne to the companys Board of Directors.
  • Zerigo Health is extremely fortunate to have them join our Board of Directors.
  • I am excited to join the Zerigo Health Board and partner with the amazing leadership team they have assembled.
  • Zerigo is dramatically improving the patient experience, ultimately leading to significant improvements in outcomes and overall health for patients.

Global Technology and Engineering Leader Rebrands as SMX

Retrieved on: 
Tuesday, November 30, 2021

SMX formed in 2019 when Smartronix and Trident Technologies joined forces, followed by the acquisition of Datastrong in 2020 and C2S Consulting Group in 2021.

Key Points: 
  • SMX formed in 2019 when Smartronix and Trident Technologies joined forces, followed by the acquisition of Datastrong in 2020 and C2S Consulting Group in 2021.
  • Rebranding as one company is the next logical step in our growth, said Peter LaMontagne, CEO of SMX.
  • SMX was recognized by Gartner as a visionary and leader in the Public Cloud Infrastructure Professional and Managed Services, Worldwide quadrant for four consecutive years and.
  • SMX, an OceanSound Partners company, is a leader in next-generation cloud, C5ISR, and advanced engineering and IT solutions operating in close proximity to clients across the U.S. and around the globe.

Smartronix Welcomes Laura Braksator as Chief Growth Officer

Retrieved on: 
Tuesday, November 16, 2021

HERNDON, Va., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Smartronix, LLC, a leader in next-generation cloud, C5ISR, and advanced engineering and IT solutions, today announced the appointment of Laura Braksator to its executive leadership team as the chief growth officer. Braksator will lead business development, capture, proposal management, marketing and communications.

Key Points: 
  • HERNDON, Va., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Smartronix, LLC ,a leader in next-generation cloud, C5ISR, and advanced engineering and IT solutions, today announced the appointment of Laura Braksator to its executive leadership team as the chief growth officer.
  • Reporting to Chief Executive Officer Peter LaMontagne, Braksator will lead enterprise-wide business development activities and oversee the corporate go-to-market strategy to drive organic growth and profitability for the organization.
  • Im thrilled to be joining the dynamic and talented team at Smartronix during such an exciting time of growth and transformation, said Braksator.
  • Prior to joining Smartronix, Braksator led business development at ASRC Federal, Perspecta, GDIT and SAIC where she was responsible for growing Civilian, Defense and Intel portfolios.

Trivver Joins IAB's Games and eSports Board of Directors

Retrieved on: 
Wednesday, August 18, 2021

NEWPORT BEACH, Calif., Aug. 18, 2021 /PRNewswire/ -- Trivver is excited to announce it has joined the Interactive Advertising Bureau's (IAB) Games and eSports Board of Directors.

Key Points: 
  • NEWPORT BEACH, Calif., Aug. 18, 2021 /PRNewswire/ -- Trivver is excited to announce it has joined the Interactive Advertising Bureau's (IAB) Games and eSports Board of Directors.
  • On the other side, advertisers have been hesitant to participate given lack of data reporting and as importantly, protecting brand identity.
  • Zoe Soon, VP of the Experience Center at the IAB states, "We're thrilled to have Joel join the IAB's Games and Esports Board of Directors.
  • Trivver is a multi-patented cutting-edge ad technology that makes promoting and selling brands in the 3D/AR/VR world simple, smart and effective.